Last reviewed · How we verify
AS (Guilin Pharmaceuticals)
AS is an artemisinin-based antimalarial compound that generates reactive oxygen species to kill malaria parasites.
AS is an artemisinin-based antimalarial compound that generates reactive oxygen species to kill malaria parasites. Used for Malaria (Plasmodium falciparum and other species).
At a glance
| Generic name | AS (Guilin Pharmaceuticals) |
|---|---|
| Also known as | Artesunate |
| Sponsor | London School of Hygiene and Tropical Medicine |
| Drug class | Artemisinin derivative |
| Target | Plasmodium heme-dependent activation |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Artemisinin derivatives work by being activated in the presence of heme iron from the malaria parasite, generating free radicals that damage parasite proteins and membranes. This mechanism is particularly effective against Plasmodium species and has been a cornerstone of malaria treatment, especially in artemisinin combination therapies (ACTs).
Approved indications
- Malaria (Plasmodium falciparum and other species)
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Abdominal pain
- Headache
Key clinical trials
- Intermittent Preventive Treatment of Malaria in School-age Children to Decrease Community Transmission (PHASE4)
- Parasite Clearance and Protection from Infection (PCPI) in Cameroon (PHASE3)
- Parasite Clearance and Protection From Infection (PCPI) in Zambia (PHASE3)
- Dihydroartemisinin-Piperaquine or Sulphadoxine-Pyrimethamine for the Chemoprevention of Malaria in Sickle Cell Anaemia (PHASE3)
- Compare the Effectiveness Between Existing Treatment and New Treatment (NA)
- SPK Study in Afghanistan (NA)
- Functional Genetic Variants Affecting Tacrolimus Trough Levels and Side Effects in Chinese Renal Transplantation.
- Efficacy and Safety Study of PDT Using Deuteporfin for Unresectable Advanced Perihilar Cholangiocarcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: